Preventing occupational exposures to antineoplastic drugs in health care settings

Ca-A Cancer Journal for Clinicians

Volumn 56, Issue 6, 2006, Pages 354-365

  Connor, Thomas H ^a   McDiarmid, Melissa A ^b  

^a NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AZACITIDINE; AZATHIOPRINE; BLEOMYCIN; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CHLORNAPHAZINE; CHLOROZOTOCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETHYLNITROSOUREA; ETOPOSIDE; LOMUSTINE; MELPHALAN; MISCELLANEOUS DRUGS AND AGENTS; PREDNISOLONE; PROCARBAZINE; SEMUSTINE; TAMOXIFEN; TENIPOSIDE; THIOTEPA; TREOSULFAN; UNINDEXED DRUG; VINCRISTINE SULFATE;

ARTICLE; CANCER RISK; CARDIOTOXICITY; DRUG CONTAMINATION; DRUG EFFECT; DRUG SAFETY; GENOTOXICITY; HEALTH CARE; HEALTH CARE PERSONNEL; HEALTH HAZARD; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; IMMUNOTOXICITY; LIVER DISEASE; LUNG DISEASE; MEDICAL SOCIETY; NEPHROTOXICITY; OCCUPATIONAL CANCER; OCCUPATIONAL DISEASE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL SAFETY; OTOTOXICITY; POLICY; PRIORITY JOURNAL; RISK ASSESSMENT; SKIN DISEASE; SKIN TOXICITY; TISSUE INJURY; WORKPLACE;

ANTINEOPLASTIC AGENTS; CARCINOGENS; HEALTH PERSONNEL; HUMANS; NEOPLASMS; OCCUPATIONAL EXPOSURE; POPULATION SURVEILLANCE; SAFETY MANAGEMENT; TECHNOLOGY, PHARMACEUTICAL; UNITED STATES; WASTE MANAGEMENT;

EID: 33845410111     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/canjclin.56.6.354     Document Type: Article

References (96)

1. World Health Organization. Cancer: WHO cancer control programme. Available at: http://www.who.int/en/. Accessed September 18, 2006.
2. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2006. CA Cancer J Clin 2006;56:106-130.
3. Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U. S. cancer burden. Cancer 2002;94;2766-2792.
4. Chabner BA, Allegra CJ, Curt GA, Calabresi P. Antineoplastic Agents, in Hardman JG, Limbird LE (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:1233-1287.
5. Tew K, Colvin OM, Chabner BA. Alkylating Agents, in Chabner BA, Longo DL (eds). Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia, PA: Lippincott-Raven; 1996:297-332.
6. National Institute for Occupational Safety and Health. NIOSH Alert: Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings. DHHS (NIOSH) Publication No. 2004-165. Washington DC: US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention; 2004.
7. Barton-Burke M, Wilkes GM. Cancer Therapies. Sudbury, MA: Jones and Bartlett Publishers; 2006.
8. Erlichman C, Moore M. Carcinogenesis: a late complication of cancer chemotherapy, in Chabner BA, Longo DL (eds). Cancer Chemotherapy and Biotherapy: Principles and Practice. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1996:45-58.
9. International Agency for Research on Cancer. IARC Monographs Database on Carcinogenic Risks to Humans. Available at: http://monographs.iarc.fr/. Accessed September 18, 2006.
10. Meirow D, Schiff E. Appraisal of chemotherapy effects on reproductive outcome according to animal studies and clinical data. J Natl Cancer Inst Monogr 2005;34:21-25.
11. Valanis BG, Vollmer WM, Labuhn KT, Glass AG. Acute symptoms associated with antineoplastic drug handling among nurses. Cancer Nurs 1993;16:288-295.
12. Valanis BG, Vollmer WM, Labuhn KT, Glass AG. Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm 1993;50:455-462.
13. McDiarmid MA. Antineoplastics, Anesthetic Agents, Sex Steroid Hormones, in Paul M (ed). Occupational and Environmental Reproductive Hazards: A Guide for Clinicians. Baltimore, MD: Lippincott Williams and Wilkins;1993:280-295.
14. Falck K, Gröhn P, Sorsa M, et al. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 1979;1:1250-1251.
15. Anderson RW, Puckett WH, Dana WJ, et al. Risk of handling injectable antineoplastic agents. Am J Hosp Pharm 1982;39:1881-1887.
16. US Food and Drug Administration, Center for Drug Evaluation and Research. CDER Human Drugs. Available at: http://www.fda.gov/cder/index.html. Accessed June 8, 2006.
17. Baker ES, Connor TH. Monitoring occupational exposure to cancer chemotherapy drugs. Am J Health Syst Pharm 1996;53:2713-2723.
18. Sorsa M, Anderson D. Monitoring of occupational exposure to cytostatic anticancer agents. Mutat Res 1996;355:253-261.
19. Sessink PJ, Bos RP. Drugs hazardous to healthcare workers. Evaluation of methods for monitoring occupational exposure to cytostatic drugs. Drug Saf 1999;20:347-359.
20. Dranitsaris G, Johnson M, Poirier S, et al. Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature. J Oncol Pharm Pract 2005;11:69-78.
21. Selevan SG, Lindbohm ML, Hornung RW, Hemminki K. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med 1985;313:1173-1178.
22. Stücker I, Caillard JF, Collin R, et al. Risk of spontaneous abortion among nurses handling antineoplastic drugs. Scand J Work Environ Health 1990;16:102-107.
23. Hemminki K, Kyyrönen P, Lindbohm ML. Spontaneous abortions and malformations in the offspring of nurses exposed to anesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. J Epidemiol Community Health 1985;39:141-147.
24. Peelen S, Roeleveld N, Heederik D, et al. Toxic Effects on Reproduction in Hospital Personnel. Reproductie-toxische effecten bij ziekenhuispersonel. Netherlands: Elsevier; 1999.
25. Valanis B, Vollmer WM, Steele P. Occupational exposure to antineoplastic agents: self-reported miscarriages and stillbirths among nurses and pharmacists. J Occup Environ Med 1999;41:632-638.
26. Zhao SF, Zhang XC, Wang QF, Bao YS. The efects of occupational exposure of female nurses to antineoplasic drugs on pregnancy outcome and embryonic development. Teratology 1996;53:94.
27. Martin S. Chemotherapy handling and effects among nurses and their offspring. Paper presented at: the Oncology Nursing Society 30th Annual Congress; April 28-May 1, 2005; Orlando, Fla. Abstract 13.
28. Skov T, Maarup B, Olsen J, et al. Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med 1992;49:855-861.
29. Skov T, Lynge E, Maarup B, et al. Risk for physicians handling antineoplastic drugs. Lancet 1990;336:1446.
30. Sessink PJ, Boer KA, Scheefhals AP, et al. Occupational exposure to antineoplastic agents at several departments in a hospital: Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health 1992;64:105-112.
31. Ros JJ, Simons KA, Verzijl JM, et al. Practical applications of a validated method of analysis for the detection of traces of cyclophosphamide on injection bottles and at oncological outpatient center. Ziekenhuisfarmacie 1997;13:168-171.
32. Hepp R, Gentschew G. External contamination of commercially available cytotoxic drugs. Krankenhauspharmazie 1998;19:22-27.
33. Delporte JP, Chenoix P, Hubert P. Chemical contamination of the primary packaging of 5-fluorouracil RTU solutions commercially available on the Belgian market. Eur Hosp Pharm 1999;5:119-121.
34. Nygren O, Gustavsson B, Ström L, Friberg A. Cisplatin contamination on the outside of drug vials. Ann Occup Hyg 2002;46:555-557.
35. Favier B, Gilles L, Ardiet C, Latour JF. External contamination of vials containing cytotoxic agents supplied by pharmaceutical manufacturers. J Oncol Pharm Pract 2003;9:15-20.
36. Mason HJ, Morton J, Garfitt SJ, et al. Cytotoxic drug contamination on the outside of vials delivered to a hospital pharmacy. Ann Occup Hyg 2003;47:681-685.
37. Connor TH, Sessink PJ, Harrison BR, et al. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three studies. Am J Health Syst Pharm 2005;62:475-484.
38. Hedmer M, Georgiadi A, Rämme Bremberg ER, et al. Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden. Ann Occup Hyg 2005;49:629-637.
39. Sessink PJ, Anzion RB, van den Broek PH, Bos RP. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci 1992;14:16-22.
40. McDevitt JJ, Lees PS, McDiarmid MA. Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med 1993;35:57-60.
41. Sessink PJ, Van de Kerkhof MC, Anzion RB, et al. Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: is skin absorption an important exposure route? Arch Environ Health 1994;49:165-169.
42. Sessink PJ, Wittenhorst BC, Anzion RB, Bos RP. Exposure of pharmacy technicians to antineoplastic agents: reevaluation after additional protective measures. Arch Environ Health 1997;52:240-244.
43. Minoia C, Turci R, Sottani C, et al. Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of healthcare personnel occupationally exposed to cyclophosphamide and ifosfamide. Rapid Commun Mass Spectrom 1998;12:1485-1493.
44. Rubino FM, Floridia L, Pietropaolo AM, et al. Measurement of surface contamination by certain antineoplastic drugs using high-performance liquid chromatography: applications in occupational hygiene investigations in hospital environments. Med Lav 1999;90:572-583.
45. Sessink PJ, Rolf M-AE, Rydèn NS. Evaluation of the PhaSeal hazardous drug containment system. Hosp Pharm 1999;34:1311-1317.
46. Connor TH, Anderson RW, Sessink PJ, et al. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Health Syst Pharm 1999;56:1427-1432.
47. Kromhout H, Hoek F, Uitterhoeve R, et al. Postulating a dermal pathway for exposure to antineoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys. Ann Occup Hyg 2000;44:551-560.
48. Favier B, Rull FM, Bertucat H, et al. Surface and human contamination with 5-fluorouracil in six hospital pharmacies. J Pharmacie Clinique 2001;20;157-162.
49. Micoli G, Turci R, Arpellini M, Minoia C. Determination of 5-fluorouracil in environmental samples by solid-phase extraction and high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 2001;750:25-32.
50. Vandenbroucke J, Robays H. How to protect environment and employees against cytotoxic agents, the UZ Ghent experience. J Oncol Pharm Practice 2001;6:146-152.
51. Connor TH, Anderson RW, Sessink PJ, Spivey SM. Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am J Health Syst Pharm 2002;59:68-72.
52. Leboucher G, Serratrice F, Bertholle V, et al. Evaluation of platinum contamination of a hazardous drug preparation area in a hospital pharmacy. Bull Cancer 2002;89:949-955.
53. Kiffmeyer TK, Kube C, Opiolka S, et al. Vapor pressures, evaporation behaviour and airborne concentrations of hazardous drugs: implications for occupational safety. Pharmeaceut J 2002;268:331-337.
54. Schmaus G, Schierl R, Funck S. Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry. Am J Health Syst Pharm 2002;59:956-961.
55. Schulz H, Bigelow S, Dobish R, Chambers CR. Antineoplastic agent workplace contamination study: the Alberta Cancer Board Pharmacy perspective. J Oncol Pharm Practice 2005;11:101-109.
56. Turci R, Sottani C, Ronchi A, Minoia C. Biological monitoring of hospital personnel occupationally exposed to antineoplastic agents. Toxicol Lett 2002;134:57-64.
57. Wick C, Slawson MH, Jorgenson JA, Tyler LS. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm 2003;60:2314-2320.
58. Acampora A, Castiglia L, Miraglia N, et al. A case study: surface contamination of cyclophosphamide due to working practices and cleaning procedures in two Italian hospitals. Ann Occup Hyg 2005;49:611-618.
59. Crauste-Manciet S, Sessink PJ, Ferrari S, et al. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Ann Occup Hyg 2005;49:619-628.
60. Zeedijk M, Greijdanus B, Steenstra FB, Uges DR. Monitoring exposure of cytotoxics on the hospital ward: measuring surface contamination of four different cytostatic drugs from one wipe sample. Eur J Hosp Pharm Sci 2005;11:18-22.
61. Larson RR, Khazaeli MB, Dillion HK. A new monitoring method using solid sorbent media for evaluation of airborne cyclophosphamide and other antineoplastic agents. Appl Occup Environ Hyg 2003;18:120-131.
62. Mason HJ, Blair S, Sams C, et al. Exposure to antineoplastic drugs in two UK hospital pharmacy units. Ann Occup Hyg 2005;49:603-610.
63. Connor TH, Shults M, Fraser MP. Determination of the vaporization of solutions of mutagenic antineoplastic agents at 23° and 37°C using a desiccator technique. Mutat Res 2000;470:85-92.
64. Burgaz S, Karahalil B, Bayrak P, et al. Urinary cyclophosphamide excretion and micronuclei frequencies in peripheral lymphocytes and in exfoliated buccal epithelial cells of nurses handling antineoplastics. Mutat Res 1999;439:97-104.
65. Deschamps F, Marinutti-Liberge V, Lamiable D. Biological monitoring of occupational exposure to cytostatic drugs with platinum. Cancer Detect Prev Online 2002; Available at: http://www.cancerprev.org/Journal/Issues/26/101/1193/ 4393. Accessed June 1, 2006.
66. Ensslin AS, Pethran A, Schierl R, Fruhmann G. Urinary platinum in hospital personnel occupationally exposed to platinum-containing antineoplastic drugs. Int Arch Occup Environ Health 1994;65:339-342.
67. Ensslin AS, Stoll Y, Pethran A, et al. Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med 1994;51:229-233.
68. Ensslin AS, Huber R, Pethran A, et al. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: urinary excretion and cytogenetics studies. Int Arch Occup Environ Health 1997;70:205-208.
69. Evelo CT, Bos RP, Peters JG, Henderson PT. Urinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide. Int Arch Occup Environ Health 1986;58:151-155.
70. Favier B, Gilles L, Desage M, Latour JF. Analysis of cyclophosphamide in the urine of antineoplastic drug handlers. Bull Cancer 2003;90:905-909.
71. Mader RM, Rizovski B, Steger GG, et al. Exposure of oncologic nurses to methotrexate in the treatment of osteosarcoma. Arch Environ Health 1996;51:310-314.
72. Nygren O, Lundgren C. Determination of platinum in workroom air and in blood and urine from nursing staff attending patients receiving cisplatin chemotherapy. Int Arch Occup Environ Health 1997;70:209-214.
73. Pethran A, Schierl R, Hauff K, et al. Uptake of antineoplastic agents in pharmacy and hospital personnel. Part 1: monitoring of urinary concentrations. Int Arch Occup Environ Health 2003;76:5-10.
74. Sessink PJ, Cerná M, Rössner P, et al. Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutat Res 1994;309:193-199.
75. McDiarmid MA, Kolodner K, Humphrey F, et al. Baseline and mutagen-induced sister chromatid exchanges in lymphocytes of pharmacists handling anticancer drugs. Environ Epidemol Tox 2000;2:254-260.
76. Pilger A, Kohler I, Stettner H, et al. Long-term monitoring of sister chromatid exchanges and micronucleus formation in pharmacy personnel occupationally exposed to cytostatic drugs. Int Arch Occup Environ Health 2000;73:442-448.
77. Hessel H, Radon K, Pethran A, et al. The genotoxic risk of hospital, pharmacy and medical personnel occupationally exposed to cytostatic drugs - evaluation by the micronucleus assay. Mutat Res 2001;497:101-109.
78. Jakab MG, Major J, Tompa A. Follow-up genotoxicological monitoring of nurses handling antineoplastic drugs. J Toxicol Environ Health 2001;62:307-318.
79. Burgaz S, Karahalil B, Canhi Z, et al. Assessment of genotoxic damage in nurses occupationally exposed to antineoplastics by the analysis of chromosomal aberrations. Hum Exp Toxicol 2002;21:129-135.
80. Yang DP, Xu SJ, Wang JX. Study on chromosomal damage among nurses occupationally exposed to antineoplastic drugs in an oncology department. Biomed Environ Sci 2002;15:268-270.
81. Laffon B, Teixeira JP, Silva S, et al. Genotoxic effects in a population of nurses handling antineoplastic drugs, and relationship with genetic polymorphisms in DNA repair enzymes. Am J Ind Med 2005;48:128-136.
82. Society of Hospital Pharmacists of Australia's Speciality Practice Committee on Parenteral Services. Guidelines for safe handling of cytotoxic drugs in pharmacy departments and hospital wards. Hosp Pharm 1981;16:17-20.
83. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic drugs in hospitals. Am J Hosp Pharm 1985;42:131-137.
84. Oncology Nursing Society Education Committee. Outcome Standards for Cancer Nursing Education. Pittsburgh, PA: Oncology Nursing Society; 1982.
85. US Department of Health and Human Services. Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs. NIH Publication 83-2621. Bethesda, MD: National Institutes of Health; 1983.
86. US Department of Health and Human Services. Recommendations for the Safe Handling of Cytotoxic Drugs. Bethesda, MD: National Institutes of Health; 1999. Available at: http://www.nih.gov/od/ors/ds/pubs/cyto. Accessed June 1, 2006.
87. National Study Commission on Cytotoxic Exposure. Recommendations for Handling Cytotoxic Agents. September 1987. Available from Louis P. Jeffrey, Sc.D., Chairman, National Study Commission on Cytotoxic Exposure, Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, MA 02115.
88. AMA Council on Scientific Guidelines. Guidelines for handling parenteral antineoplastics. JAMA 1985;253:1590-1592.
89. US Department of Labor, Occupational Safety and Health Administration. Work practice guidelines for personnel dealing with cytotoxic (antineoplastic) drugs. OSHA Publication 8-1.1. Washington DC: Occupational Safety and Health Administration; 1986.
90. Occupational Safety and Health Administration. OSHA Technical Manual, TED 1-0.15A, Section VI, Chapter 2, January 20, 1999. Available at: http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html#2. Accessed June 1, 2006.
91. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm 1990;47:1033-1049.
92. American Society of Health-System Pharmacists. ASHP Guidelines on Handling Hazardous Drugs. Am J Health Syst Pharm 2006;63:1172-1193.
93. Polovich M, White JM, Kelleher LO, eds. Chemotherapy and Biotherapy Guidelines and Recommendations for Practice. Pittsburgh, PA: Oncology Nursing Society; 2005. Available at: http://www.guideline.gov/summary/summary.aspx? doc_id=8337. Accessed August 21, 2006.
94. Soule RD. Industrial Hygiene Engineering Controls, in Patty FA (ed). Patty's Industrial Hygiene and Toxicology. 3rd Ed. New York, NY: John Wiley & Sons; 1978:771-823.
95. Peterson AM, Barton-Burke M. Introduction to chemotherapy drugs, in Wilkes GM, Barton-Burke M (eds). Oncology Nursing Drug Handbook. Sudbury, MA: Jones and Bartlett Publishers;2005:255-288.
96. Smith CA. Managing pharmaceutical waste: what pharmacists should know. J Pharm Soc WI 2002;November/December:17-22.